All sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS18
PHASE 3 / 2-34
RECRUITING13
READOUTS ≤12 MONTHS9
READOUT SLIPPED >6 MO21%

Delay Index: of 14 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Suzhou Zelgen Biopharmaceuticals Co.,Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
ZG006
NCT06440057
P1/2RecruitingNeuroendocrine Carcinoma782026-05
ZG006
NCT05978284
P1/2RecruitingSmall Cell Lung Cancer; Neuroendocrine Carcinoma542026-09 (+12 mo)
ZGGS18 for Injection
NCT05584800
P1/2RecruitingAdvanced Solid Tumor2222026-11-01 (+36 mo)
ZG005 for Injection
NCT06883526
P1/2RecruitingLymphoma602027-04
ZG005 for Injection
NCT06903377
P1/2RecruitingNon-small Cell Lung Cancer502027-04
ZG006
NCT06283719
P1/2RecruitingSmall Cell Lung Cancer; Neuroendocrine Cancer2652027-04 (+12 mo)
ZGGS18 for Injection
NCT06938880
P1/2RecruitingAdvanced Solid Tumor602027-05
ZG005 for Injection
NCT06927687
P2Active, not recruitingAdvanced Solid Tumor502027-05
ZG005
NCT07080216
P1/2RecruitingCervical Cancer1202027-08
ZG006
NCT07038096
P1/2RecruitingSmall Cell Lung Cancer; Neuroendocrine Carcinoma3502027-09
ZG005
NCT07142837
P1/2Not yet recruitingAdvanced Solid Tumor1532027-10
ZG005
NCT07099547
P2RecruitingBiliary Tract Carcinoma602027-12
ZG006
NCT07024277
P2Not yet recruitingNeuroendocrine Prostate Cancer602027-12
ZG006
NCT07595913
P3Not yet recruitingNeuroendocrine Carcinoma2402028-06
ZG006
NCT07189455
P3RecruitingSmall-cell Lung Cancer4202028-10
ZG006
NCT07258121
P1/2RecruitingSolid Tumor4002028-12
ZG005 for Injection
NCT07813572
P3RecruitingHepatocellular Carcinoma6002031-09
ZG005 for Injection
NCT07833839
P3Not yet recruitingNeuroendocrine Carcinomas (NEC)4402031-10